Retracted and Republished From: "The Current State of Research on Influenza Antiviral Drug Development: Drugs in Clinical Trial and Licensed Drugs"

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2024 Mar 29

PMID 38551343

Authors

Yanbai Li

Shanshan Huo

Zhe Yin

Zuguang Tian

Fang Huang

Peng Liu

Yue Liu

Fei Yu

Affiliations

Soon will be listed here.

Abstract

Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the Food and Drug Administration are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. These recommended antivirals are currently effective for major subtypes of IVs as the compounds target conserved domains in neuraminidase or polymerase acidic (PA) protein. However, this trend may gradually change due to the selection of antiviral drugs and the natural evolution of IVs. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.

Citing Articles

Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export.

Cao L, She Z, Zhao Y, Cheng C, Li Y, Xu T Emerg Microbes Infect. 2024; 13(1):2387910.

PMID: 39087696 PMC: 11321118. DOI: 10.1080/22221751.2024.2387910.

A Cyclic Peptide Based on Pheasant Cathelicidin Inhibits Influenza A H1N1 Virus Infection.

Pei Y, Chen Z, Zhao R, An Y, Yisihaer H, Wang C Antibiotics (Basel). 2024; 13(7).

PMID: 39061288 PMC: 11273436. DOI: 10.3390/antibiotics13070606.

Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis: Exploring Therapeutic Options.

Soni S, Antonescu L, Ro K, Horowitz J, Mebratu Y, Nho R Am J Pathol. 2024; 194(10):1807-1822.

PMID: 39032604 PMC: 11423761. DOI: 10.1016/j.ajpath.2024.06.004.

References

Kim C, Lew W, Williams M, Liu H, Zhang L, Swaminathan S . Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997; 119(4):681-90. DOI: 10.1021/ja963036t. View

Heneghan C, Onakpoya I, Thompson M, Spencer E, Jones M, Jefferson T . Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2547. PMC: 3981976. DOI: 10.1136/bmj.g2547. View

Zheng W, Fan W, Zhang S, Jiao P, Shang Y, Cui L . Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export. Cell Rep. 2019; 27(6):1875-1885.e5. DOI: 10.1016/j.celrep.2019.04.053. View

Jing X, Ma C, Ohigashi Y, Oliveira F, Jardetzky T, Pinto L . Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A. 2008; 105(31):10967-72. PMC: 2492755. DOI: 10.1073/pnas.0804958105. View

Nawrocki J, Weiss S, Davidson M, Sprecher D, Schwartz S, Lupien P . Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995; 15(5):678-82. DOI: 10.1161/01.atv.15.5.678. View

Webster D, Li Y, Bastien N, Garceau R, Hatchette T . Oseltamivir-resistant pandemic H1N1 influenza. CMAJ. 2011; 183(7):E420-2. PMC: 3080559. DOI: 10.1503/cmaj.100313. View

Hsieh Y, Dugas A, LoVecchio F, McBryde B, Ricketts E, Saliba-Shaw K . Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study. Influenza Other Respir Viruses. 2020; 15(1):121-131. PMC: 7767951. DOI: 10.1111/irv.12794. View

Kirkpatrick E, Qiu X, Wilson P, Bahl J, Krammer F . The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018; 8(1):10432. PMC: 6041311. DOI: 10.1038/s41598-018-28706-1. View

Walsh P, Schnadower D, Zhang Y, Ramgopal S, Shah S, Wilson P . Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020. JAMA Pediatr. 2022; 176(11):e223261. PMC: 9486642. DOI: 10.1001/jamapediatrics.2022.3261. View

10.

Abusalamah H, Reel J, Lupfer C . Pyruvate affects inflammatory responses of macrophages during influenza A virus infection. Virus Res. 2020; 286:198088. PMC: 7345311. DOI: 10.1016/j.virusres.2020.198088. View

11.

Jefferson T, Jones M, Doshi P, Del Mar C . Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009; 339:b5106. PMC: 2790574. DOI: 10.1136/bmj.b5106. View

12.

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View

13.

McKimm-Breschkin J . Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013; 7 Suppl 1:25-36. PMC: 4942987. DOI: 10.1111/irv.12047. View

14.

Ali S, Takas T, Nyborg A, Shoemaker K, Kallewaard N, Chiong R . Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza. Antimicrob Agents Chemother. 2018; 62(11). PMC: 6201130. DOI: 10.1128/AAC.00694-18. View

15.

Narasaraju T, Yang E, Perumal Samy R, Ng H, Poh W, Liew A . Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011; 179(1):199-210. PMC: 3123873. DOI: 10.1016/j.ajpath.2011.03.013. View

16.

Meindl P, Bodo G, Palese P, Schulman J, Tuppy H . Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974; 58(2):457-63. DOI: 10.1016/0042-6822(74)90080-4. View

17.

Hulseberg C, Feneant L, Szymanska-de Wijs K, Kessler N, Nelson E, Shoemaker C . Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019; 93(8). PMC: 6450122. DOI: 10.1128/JVI.02185-18. View

18.

Lee P, Yoshida R, Ekiert D, Sakai N, Suzuki Y, Takada A . Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A. 2012; 109(42):17040-5. PMC: 3479480. DOI: 10.1073/pnas.1212371109. View

19.

Ye Z, Liu T, Offringa D, McInnis J, Levandowski R . Association of influenza virus matrix protein with ribonucleoproteins. J Virol. 1999; 73(9):7467-73. PMC: 104273. DOI: 10.1128/JVI.73.9.7467-7473.1999. View

20.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K . Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49(3):981-6. PMC: 549233. DOI: 10.1128/AAC.49.3.981-986.2005. View